FAS and steatosis: Moreover, because FGF21 is known to modulate the hepatic metabolic pathway to suppress steatosis [25], the observed reduced FAS expression and lipid accumulation by E2 and coumestrol in the liver (Figure 3) might be associated with increased FGF21 production.